News TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
13.78 ^USD	-1.50%		-2.68%	-19.32%

Apr. 18	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
Apr. 18	Sector Update: Health Care	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	Apr. 19	AQ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Sector Update: Health Care	Apr. 18	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	Apr. 18	MT
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	Apr. 18	AQ
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis	Apr. 18	AQ
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	Apr. 18	CI
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	Apr. 16	AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	Mar. 13	MT
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	Mar. 08	AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	Mar. 04	AQ
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	Mar. 01	MT
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	Mar. 01	AQ
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	Feb. 29	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Feb. 28	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	Feb. 28	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	Feb. 28	MT
Transcript : TG Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
TG Therapeutics: Q4 Earnings Snapshot	Feb. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Summary

Filters